There is evidence that nitric oxide (NO) is required for the normal increases in skeletal muscle glucose uptake during contraction, but the mechanism(s) involved have not been elucidated. We examined whether NO regulates glucose uptake during skeletal muscle contractions via cGMPdependent or cGMP-independent pathway(s). Isolated extensor digitorum longus (EDL) muscles from mice were stimulated to contract ex vivo and potential NO signaling pathways were blocked by the addition of inhibitors to the incubation medium. Contraction increased (P<0.05) NOS activity (~40%) and DCF fluorescence (a marker of oxidant levels; ~95%), which was prevented with a NOS inhibitor (L-NMMA), and antioxidants (non specific antioxidant, NAC; thiol reducing agent, DTT), respectively. L-NMMA and NAC both attenuated glucose uptake during contraction by ~50% (P<0.05) and their effects were not additive. Neither the guanylate cyclase inhibitor ODQ, which prevents the formation of cGMP, the cGMP-dependent protein (PKG) inhibitor Rp-8-Br-PET-cGMPS nor white light, which breaks S-nitrosylated bonds, affect glucose uptake during contraction, however DTT attenuated (P<0.05) contraction-stimulated glucose uptake (by 70). NOS inhibition and antioxidant (NAC) treatment reduced contractionstimulated increases in protein S-glutathionylation and tyrosine nitration (P<0.05), without affecting AMPK or p38 MAPK phosphorylation. In conclusion, we provide evidence to suggest that NOS-derived oxidants regulate skeletal muscle glucose uptake during ex vivo contractions via a cGMP/PKG, AMPK and p38 MAPK independent pathway. In addition, it appears that NO and ROS may regulate skeletal muscle glucose uptake during contraction through a similar pathway.
INTRODUCTION
Both insulin-stimulation and contraction of skeletal muscle facilitate GLUT4 translocation to the cell membrane, and glucose uptake into muscle fibres (10) . Although the mechanisms through which contraction stimulates glucose uptake have not yet been completely elucidated, they differ from that of insulin signaling (37) . Possible signaling intermediates of contraction-stimulated skeletal muscle glucose uptake include AMP-activated protein kinase (AMPK) (17) , nitric oxide (NO) (42) , reactive oxygen species (ROS) (44), and calmodulindependent kinase (CaMK) (51).
NO and ROS are highly interrelated molecules (9) and their generation in skeletal muscle is elevated during contraction (4, 38, 44) . We have evidence that NO synthase (NOS) inhibition attenuates increases in skeletal muscle glucose uptake during exercise in humans (8) , in situ contractions in rats (42) , and mouse EDL muscle contracted ex vivo (32). Although NO has also been shown to be involved in regulating contraction-stimulated skeletal muscle glucose uptake/transport in other rodent models (3, 41) , this is an equivocal finding (15, 18, 43) . The contradictory results are likely due to methodological inconsistencies (for details see 31). Like NO, the attenuation of contraction-stimulated increases in skeletal muscle ROS levels with antioxidants attenuates increases in glucose uptake during contractions ex vivo (32, 44) . This suggests that NO and ROS are both involved in the regulation of glucose uptake during skeletal muscle contractions ex vivo and given their close relationship it is possible that they interact to this end.
Studies investigating the mechanism(s) through which NO regulates skeletal muscle glucose uptake have focused largely on NO donor-stimulated skeletal muscle glucose uptake, rather than that produced endogenously during contraction (19, 21, 50, (52) (53) (54) . The prevention of NO donor-mediated increases in skeletal muscle cyclic guanosine monophosphate (cGMP) formation and cGMP-dependent protein kinase (PKG) activity, through the inhibition of guanylate cyclase (GC), prevents NO donor-induced increases in glucose uptake at rest (54).
Similarly, the cGMP analog, 8-bromo-cGMP, can increase resting skeletal muscle glucose uptake (52), suggesting that NO mediates glucose uptake in skeletal muscle via the traditional NO/cGMP/PKG signaling pathway (48). Like NO-donors, contraction-stimulated increases in skeletal muscle NO production elevates muscle cGMP concentration (27) , and therefore cGMP is likely to contribute to the regulation of skeletal muscle glucose uptake during contraction.
However, NO often exerts its effects independent of the cGMP-PKG signaling pathway, via various post-translational signaling events such as the addition of a NO group (S-nitrosylation) or glutathione (S-glutathionylation) to cysteine sulfhydryls on proteins, or peroxynitrite nitration of protein tyrosine residuals (tyrosine nitration) (13, 48, 55) . Importantly all of these signaling events require, or have the potential to be modulated by ROS (9, 30) . Therefore, the mechanism(s) though which NO stimulates skeletal muscle glucose uptake during contraction has yet to be investigated. Furthermore, whether reactive oxygen and nitrogen (such as NO) species regulate skeletal muscle glucose uptake through a similar pathway during contraction has not been examined.
The purpose of this study was to investigate the mechanism(s) through which NO regulates glucose uptake during skeletal muscle contractions ex vivo. We tested the hypothesis that NO increases skeletal muscle glucose uptake during contractions via cGMP-dependent andindependent pathways that involve signaling through interaction with ROS.
RESEARCH DESIGN AND METHODS

Animals
This study used male C57Bl/6 mice at 12-14 weeks. Mice were maintained in an environmentally controlled room at 21°C with a 12 hour light-dark cycle (light 06: 30-18:30) , and had ad libitum access to standard rodent chow and water. The experiments were approved by the Animal Experimentation Ethics Committee of The University of Melbourne, and conformed to the Australian code of practice for the care and use of animals for scientific purposes, as described by the National Health and Medical Research Council (Australia). 
Materials and Antibodies
2-deoxy-D-[1,2-
Muscle dissection, incubation and contraction protocol
The extensor digitorum longus (EDL) muscles were carefully excised from mice that were anesthetised deeply with sodium pentobarbital (60 mg·kg -1 i.p; Rhone Merieux, Pinkenba, Queensland, Australia). EDL muscles were used in this study since nNOS is more highly expressed in muscle containing primarily glycolytic fibres (26, 32) , and NO appears to play a greater role in regulating glucose uptake in EDL muscles than in soleus (which contain primarily oxidative muscle fibers) muscles of mice when contracted ex vivo (32). The proximal tendon was tied to a force transducer (PanLab, Spain) using 5/0 silk suture and the muscles suspended vertically in incubation chambers (Radnoti, Monrovia, CA) that were filled with Ringer solution ((in mM): NaCl 118.5, NaHCO 3 24.7, KCl 4.74, MgSO 4 1.18, KH 2 PO 4 1.18, CaCl 2 2.5, mannitol 8, sodium pyruvate 2, 0.01% BSA, pH 7.4), maintained at 30°C and continuously oxygenated with 95% O 2 and 5% CO 2 (Carbogen; BOC Gases; Victoria, Australia). Ringers solution was maintained at 30ºC since this temperature has previously been reported to be optimal for maintaining muscle function and measuring glucose uptake ex vivo (22) . However, it is acknowledged that this may have reduced oxidant activity compared to physiological temperature (37ºC) (2) .
Muscles were stimulated with square wave electrical pulses generated by a Grass S48 stimulator, amplified by an EP500B power amplifier (Audio Assemblies, Cambellfield, Victoria, Australia) and delivered to two platinum plate electrodes that flanked the muscle preparation but did not touch it. Optimal muscle length (L o ) was determined from isometric twitch contractions (14)), the thiol reducing agent dithiothreitol (DTT, 10mM (1)), the peroxynitrite scavenger urate (10mM (40, 46) ) or white light (dissection lamp 10 cm from incubating muscle; Novaflex, world precision instruments, Sarasota, FL) to break S-nitrosylated bonds (6, 7) . Light from the dissection lamp diffused through the isolated muscle and therefore is likely to break any S-nitrosylation bonds that may form, unlike indirect expose to white light from laboratory lighting (24) . Contracted muscles were then stimulated (pulse durations: 600 ms at a frequency of 60Hz for 25 contractions·min -1 ) during the final 10 min of incubation. This stimulation protocol has been previously shown to be sufficient to recruit all motor units and elicit maximum force (29). Non-contracted (resting) muscles were incubated in the presence or absence of the NO-donor diethylenetriamine/NO (Deta/NO, 500μM), Deta/NO+ODQ, L-NMMA, NAC, DTT, or urate for 40 min. At the conclusion of the incubation/contraction protocol, the muscles were quickly cut from the sutured attachments and rapidly frozen in liquid nitrogen for future biochemical analyses. Separate muscles were used for glucose uptake, immunoblotting, NOS activity and oxidant levels.
Glucose uptake measurements
Glucose uptake was determined during the final 5 min of contraction and over 5 min of recovery in contracted muscles (22, 32) . In non-contracted (resting) muscles, glucose uptake was determined during the final 10 min of incubation. To measure glucose uptake the muscle incubation buffer was exchanged for one containing 1 mM 2-deoxy-D-[1,2- 
Oxidant levels and NOS activity
The fluorescent probe 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA; Molecular Probes, Eugene, OR) was used to measure oxidant levels in muscle sections. Immediately following contraction or incubation at rest, muscles were rapidly mounted in OCT and frozen in isopentane cooled in liquid nitrogen. DCFH-DA (5μM) was added to 10μm EDL muscle crosssections, covered with a cover-slip and allowed to dry overnight at room temperature. The oxidized derivative of DCFH-DA, dichloroflourescein (DCF), was measured using confocal microscopy (480 nm excitation, 520 nm emissions; Zeiss LSM-510 Meta confocal microscope, Carl Zeiss Microimaging, Thornwood, NY) and emission intensity determined using Zeiss LSM-510 accusation and analysis software. We measured DCF fluorescence as an index of intracellular oxidant levels in accordance with previous studies (34) . All procedures were carried out in low light to avoid photo-oxidation. NOS activity was determined in separate EDL muscles by measuring the conversion of labeled L-arginine to labeled L-citrulline (NOS activity assay, Cayman Chemicals, Ann Arbor, MI).
Statistical Analysis
All data are expressed as mean ± SEM. Results were analyzed using SPSS statistical package using one-factor ANOVA (treatment) and one-factor repeated measure ANOVA for contraction forces (treatment and time). If the ANOVA revealed a significant treatment effect, or a treatment by time interaction, specific differences between mean values were identified using the Fisher's least significance difference test. The level of significance was set at P<0.05.
RESULTS
Muscle contraction
Treatment of muscles with the peroxynitrite scavenger, urate, reduced peak tetanic force (normalized to muscle mass) by ~37% (P=0.02; Figure 1C ). Peak force was not affected by any other treatment (P>0.05; Figure 1A and C). Peak force was obtained within the first 10s of the contraction protocol and declined thereafter (P<0.001; Figure 1B and D). The rate of decline from peak force was not affected by any treatment (P>0.05; Figure 1B and D) .
Oxidant levels and NOS activity
Basal oxidant levels in muscles were increased ~95% with contraction ( Figure 2A and B). Urate tended (P=0.059) to attenuate this increase ( Figure 2B ), and the non-specific antioxidant, NAC, and the thiol reducing agent, DTT, prevented contraction stimulated increases in oxidant activity (P>0.05 vs basal; Figure 2B ). Contraction increased NOS activity in EDL muscles by ~40% and the NOS inhibitor, L-NMMA, reduced NOS activity during contraction to ~35% of basal activity ( Figure 2C ).
Contraction and Deta/NO stimulated glucose uptake
Contraction increased muscle glucose uptake by 1.8-2.3-fold (P<0.05, Figure 3A , B and 4). NAC and L-NMMA attenuated the increase in glucose uptake during contraction, similarly, by ~50% (P<0.05) and co-treatment of L-NMMA with NAC did not have an additive effect on the magnitude of the reduction ( Figure 3A) . The GC inhibitor, ODQ, which prevents cGMP formation (16), did not affect contraction-stimulated glucose uptake ( Figure 3B ) but prevented the 1.5-fold increase (P=0.01) in glucose uptake stimulated by the NO-donor Deta/NO ( Figure   3C ). Furthermore, muscle glucose uptake during contraction in the presence (1.84 ± 0.12 
S-glutathionylation and tyrosine nitration
Contraction increased S-glutathionylation of protein bands at ~270 kDa and ~37 kDa by 1.8-, and 1.5-fold (P<0.05, Figure 5A ), respectively. The contraction-stimulated increase in Sglutathionylation at ~270 kDa was prevented by NAC but unaffected by L-NMMA ( Figure 5A ).
L-NMMA and NAC both attenuated the contraction-stimulated increase in S-glutathionylation at ~37 kDa (P<0.05; Figure 5A ). Contraction increased tyrosine nitration of a protein band at ~37 kDa by 1.7-fold (P=0.01), and this increase was prevented by L-NMMA and NAC ( Figure 5B ).
Neither contraction nor treatment significantly affected protein S-glutathionylation or tyrosine nitration of any other visible protein bands. 
Contraction-stimulated AMPK, ACCβ, p38 MAPK and nNOS phosphorylation
Basal glucose uptake, resting tension and AMPK signaling
Resting glucose uptake in EDL muscles was reduced ~25% by NAC (P=0.02) ( Figure   7B ), but was not affected by L-NMMA or DTT (P>0.05; Figure 7A ). Although NAC reduced basal glucose uptake, the delta glucose uptake for NAC (the difference between basal + NAC and contraction + NAC glucose uptake) was different (P<0.05) from the delta of control muscles (difference between basal and contraction glucose uptake) indicating that NAC attenuated the increase in glucose uptake during contraction independent of its affects on basal glucose uptake.
Urate increased (P<0.05) resting (passive) muscle tension (from 1 min; Figure 7C ) and this was accompanied by ~3-fold increase (P=0.002) in resting muscle AMPKα Thr 172 phosphorylation ( Figure 7B ) and ~1.8-fold increase in glucose uptake (P<0.001; Figure 7A ). There was a slight but significant increase (P<0.05) in passive tension with DTT treatment which appeared to be transient ( Figure 7C ).
DISCUSSION
The major findings of this study were that (a) the attenuation of increases in both NOS activity and ROS levels during skeletal muscle contractions ex vivo by L-NMMA and NAC, respectively, attenuates glucose uptake; (b) co-treatment of L-NMMA and NAC does not have an additive affect on the attenuation of skeletal muscle glucose uptake during contraction; (c) the guanylate cyclase inhibitor, ODQ, attenuates NO donor-stimulated glucose uptake but neither ODQ nor the PKG inhibitor, Rp-8-Br-PET-cGMPS, affects skeletal muscle glucose uptake during contraction; (d) L-NMMA and NAC attenuate contraction-stimulated increases in muscle protein S-glutathionylation and tyrosine nitration at ~37 kDa without affecting AMPK or p38 MAPK phosphorylation; and (e) the thiol reducing agent (DTT) and peroxynitrite scavenger (urate) attenuates contraction-stimulated increases in skeletal muscle glucose uptake, however, urate appeared to have several non-specific effects which confound interpretation of this data and are discussed in detail below. Taken together these findings suggest that NOS-derived oxidants regulate skeletal muscle glucose uptake during ex vivo contractions via a cGMP-independent pathway. In addition, this data suggests that ROS and NO may be involved in the regulation of skeletal muscle glucose uptake during contractions ex vivo through a similar pathway that does not require AMPK or p38 MAPK phosphorylation, but may involve signaling through peroxynitrite and S-glutathionylation. However, whether a causal relationship exists between skeletal muscle glucose uptake during contraction and peroxynitrite and S-glutathionylation signaling now needs to be examined.
Previously we have shown that the inhibition of NOS attenuates glucose uptake during muscle contractions (8, 25, 32, 42) . In support of these findings we show here that preventing increases in NOS activity during ex vivo contractions ( Figure 2C ) of mouse EDL muscles attenuates increases in glucose uptake ( Figure 3A) . The mechanism(s) through which NO stimulates skeletal muscle glucose uptake during contraction had not been examined previously, although inhibition of GC with LY-83584 has been shown to prevent NO donor-stimulated increases in cGMP formation, glucose uptake and PKG activity in rat skeletal muscles at rest (54). We have confirmed these findings by showing that the specific GC inhibitor, ODQ (16), prevented the increase in resting muscle glucose uptake stimulated by the NO donor, Deta/NO ( Figure 3C ). However, surprisingly, ODQ did not affect skeletal muscle glucose uptake during contraction ( Figure 3B ). We were unable to measure skeletal muscle cGMP formation following contraction. Since cGMP is broken down extremely quickly by cGMP-specific phosphodiesterase (PDE) in the absence of PDE inhibitors (5), we believe we did not freeze muscle fast enough following contraction to see an increase in cGMP content. However, Lau et al. (27) freeze clamped muscles following contraction and reported that contraction increases muscle cGMP to similar as NO-donors. Since ODQ inhibited NO donor-stimulated glucose uptake which requires cGMP signaling (53), we are confident that ODQ prevented any increases in cGMP formation that may have occurred during contraction. In addition, we report that the PKG inhibitor (Rp-8-Br-PET-cGMPS) also does not affect glucose uptake during contraction.
This suggests that in contrast to NO donor-stimulated glucose uptake in resting muscle (52-54), during skeletal muscle contraction NO regulates glucose uptake through a cGMP-PKGindependent pathway. Interestingly, NO has been shown to regulate glucose uptake in adipocytes through a cGMP-independent mechanism possibly involving S-nitrosylation (23). However, Snitrosylation does not appear to be involved in regulating skeletal muscle glucose uptake during contraction because in the current study white light, which breaks S-nitrosylation bonds (6, 7), did not affect the increase in contraction-stimulated glucose uptake (Figure 4) . However, further work is needed to ensure that white light prevents the formation of all S-nitrosyl bonds during contraction to confirm that S-nitrosylation is not involved in regulating skeletal muscle glucose uptake during contraction. This is particularly important because S-nitrosylation can have a direct effect on ROS signaling via S-glutathionylation (30).
In agreement with previous studies, we found that contraction increases oxidant levels in skeletal muscle (39, 44) , and that this increase can be prevented by antioxidant treatment ( Figure   2 ). DCF fluorescence was measured as a marker of muscle ROS levels, and contraction-induced increases in DCF fluorescence were prevented by the antioxidants NAC and DTT (Figure 2 ). This suggests that although DCFH can be oxidized to DCF by reactive nitrogen species (33) We observed that the antioxidants NAC, DTT and urate attenuated muscle contractionstimulated glucose uptake ex vivo ( Figure 3A and 4) . It must be acknowledged, however, that it is not known whether DTT or urate inhibition of increases in glucose uptake is specific to contraction-stimulated increases. Regardless, these data support previous findings that the antioxidants NAC, ebselen, catalase and MnTBAP attenuate stretch (11) and contractionstimulated increases in skeletal muscle glucose uptake (44). Furthermore, Sandstrom et al. (44) showed that the increases in skeletal muscle glucose uptake and AMPK signaling during contraction were attenuated in parallel by NAC treatment, while Chambers et al. (11) provided some evidence that ROS may regulate stretch-stimulated skeletal muscle glucose uptake via p38 MAPK (p38). In contrast, we found that the antioxidants NAC and DTT attenuated contractionstimulated glucose uptake independent p38 phosphorylation, and NAC, DTT, and urate did not affected AMPK phosphorylation during contraction ( Figure 6 ). The lack of p38 effect in our current study suggests that stretch and contraction stimulate glucose uptake through separate pathways. However, the discrepancy between Sandstrom et al. The attenuation of contraction-stimulated muscle glucose uptake by combined NOS inhibition and NAC treatment was not additive ( Figure 3A ). This may suggest that NOS uncoupling, resulting in the production of superoxide as well as NO (28), may play a role in regulating skeletal muscle contraction stimulated glucose uptake. Alternatively, or concurrently, it may be that during contraction there is some degree of overlap between the pathways through which NO and ROS regulate skeletal muscle glucose uptake. Superoxide and NO interact to form ONOO -which can cause the tyrosine nitration of proteins (46) . Indeed, tyrosine nitration increased with contraction and this increase was prevented by NAC treatment and NOS inhibition ( Figure 5 ). Furthermore, ONOO -promotes protein S-glutathionylation (30); oxidative or nitrosative stress induced reversible formation of mixed disulfides between protein sulfide groups and glutathione (13) which is becoming increasingly recognized as the redox equivalent of phosphorylation in regulating protein signaling (13, 30). As such, we found that contraction stimulated S-glutathionylation is attenuated by a general antioxidant (NAC).
Interestingly, the contraction-induced increase in skeletal muscle glucose uptake, Sglutathionylation and tyrosine nitration of protein bands at ~37 kDa was attenuated by NOS inhibition and NAC treatment ( Figure 3A, 4 and 5 ). This suggests that during contraction ROS and NO interact to alter protein S-glutathionylation and tyrosine nitration, and it is possible that this may play a role in the regulation of skeletal muscle glucose uptake during contraction, Incubation of the skeletal muscle with urate, an ONOO -scavenger (40, 46) , reduced initial contraction force and inhibited muscle signaling (ACCβ and p38) during contraction, independent of NOS inhibition ( Figure 6 ). This indicates that urate is having effects on skeletal muscle independent of ONOO -scavenging. Furthermore, urate stimulated an increase in resting muscle passive tension ( Figure 7C ) which is likely to have caused the increase in resting muscle AMPK phosphorylation and glucose uptake ( Figure 7A and B) (20) . Although skeletal muscle glucose uptake during contraction may not be dependent on force production per se (45), the various effects of urate on the muscle likely confound interpretation of ONOO -effects on skeletal muscle glucose uptake during contraction. It was notable, however, that the increase in resting muscle glucose uptake with urate was similar to that seen after the combination of urate and contraction ( Figure 4) ; suggesting that urate prevented any further increase in skeletal muscle glucose uptake during contraction. Therefore, investigating the role of ONOO -in regulating skeletal muscle glucose uptake during contraction requires further attention.
In conclusion, this study provides the first evidence to suggest that that during ex vivo contractions NOS-derived oxidants regulate skeletal glucose uptake through a cGMP-PKG independent pathway that does not involve p38 MAPK or AMPK signaling. Furthermore, we provide evidence that NO and ROS may regulate skeletal muscle glucose uptake during contraction ex vivo through a similar pathway, with some suggestion that signaling through peroxynitrite and S-glutathionylation signaling may be involved. 
